葛兰素史克的首创抗生素再次在III期试验中取得成功，即将进入监管审批阶段。 - Suppr

GSK's first-in-class antibiotic secures another phase III win, approaches regulatory run.

Mullard Asher

Nat Rev Drug Discov. 2024 Apr;23(4):239. doi: 10.1038/d41573-024-00047-x.

Abstract

摘要

Nat Rev Drug Discov. 2024 Apr;23(4):239. doi: 10.1038/d41573-024-00047-x.

Drug Saf. 2021 Dec;44(12):1375-1390. doi: 10.1007/s40264-021-01121-8. Epub 2021 Oct 25.

Vaccine. 2018 Feb 8;36(7):986-996. doi: 10.1016/j.vaccine.2018.01.005. Epub 2018 Jan 12.

Infect Dis Ther. 2022 Feb;11(1):463-483. doi: 10.1007/s40121-021-00571-y. Epub 2021 Dec 27.

Drug Saf. 2020 Mar;43(3):265-279. doi: 10.1007/s40264-019-00893-4.

Curr Opin Mol Ther. 2009 Jun;11(3):337-45.

Vaccine. 2007 Sep 27;25 Suppl 2:B61-71. doi: 10.1016/j.vaccine.2007.06.038.

Nat Rev Drug Discov. 2010 Jul;9(7):506. doi: 10.1038/nrd3223.

Lancet. 2024 Feb 10;403(10426):526-527. doi: 10.1016/S0140-6736(23)01913-X.

Open Forum Infect Dis. 2023 May 8;10(5):ofad249. doi: 10.1093/ofid/ofad249. eCollection 2023 May.

bioRxiv. 2024 Dec 27:2024.12.27.630553. doi: 10.1101/2024.12.27.630553.

iScience. 2024 Sep 16;27(10):110967. doi: 10.1016/j.isci.2024.110967. eCollection 2024 Oct 18.

20分钟写一篇综述，助力文献阅读效率提升50倍。

大模型驱动的PubMed中文搜索引擎

学术文献翻译模型，支持多种主流文档格式。